Navigation Links
PreMD Inc. Completes Debenture Financing
Date:3/12/2008

ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit http://www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions. In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new
'/>"/>

SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. PreMD Inc. Signs Agreement with Cosmetics Conglomerate
2. PreMD Inc. Announces Debenture Financing
3. PreMD Initiates FDA Review Process and Provides Corporate Update
4. PreMD Announces FDA Decision on POC Skin Cholesterol Test
5. PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product
6. PreMD Inc. Provides Corporate Update
7. PreMD Provides Update on 510(k) Application for PREVU(x) POC
8. Gentiva(R) Health Services Completes Acquisition of Major Home Health Provider in CON State of Mississippi
9. Roche Completes Tender Offer for Ventana Shares
10. Nyer Medical Group Completes Acquisition of Minority Interest in Pharmacy Chain Subsidiary; Former Minority Shareholders Invest in Nyer Medical Group and Sign 3-Year Employment Agreements
11. KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2009)... HealthSmart, an innovative healthcare benefit...ccessfully completed a recapitalization with Silve...r lenders. Silver Point Capital, L.P. is a privat... This recapitalization allows the Company to cont...y. , , (PRWEB) November ...
(Date:11/21/2009)...N, Nov. 21 Tonight, in ...to Senator Reid,s version of the government takeov... items included in this bill; like the public opti...nment funding for elective abortion, which is the ...ly the bill provides subsidies for private plans t...
(Date:11/21/2009)...ON, Nov. 21 A regional ...ocerciasis (river blindness) in the Americas has s... in recent years, as evidenced by a 31% decrease i...ministration in six endemic countries. Results we...e American Society of Tropical Medicine and Hygien...
(Date:11/21/2009)... Innovative medical apparel company launches m... San Clemente, Calif. (PRWEB) Nov...ough medical apparel, today announced the launch o...ica 2009, a leading international trade fair for t...edelita inaugurates its men,s collection with thre...
(Date:11/21/2009)... Linwood Group ask whether there is a secret t... , London, UK (PRWEB) Nove... to one in three of the adult UK population drinki...lcohol-related liver disease*, it is hardly a surp...itation programmes and residential centres for hel...
Breaking Medicine News(10 mins):Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:FRC: Senate Votes to Proceed with Abortion Funding Debacle 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4
...y, ALLEGAN, Mich., May 21 Perrigo Company,(Nasda...ed into a,collaborative agreement with Cobrek Phar...maceuticals Inc., a privately owned company that s... foam, a $34,million branded pharmaceutical produc...
.... (NYSE: CNO ) at the company,s annual meeting to...expiring at next year,s annual meeting;, -- A... incorporation to eliminate the plurality voti...LP as the company,s independent registered pub...
...have identified a biological explanation for the l...allergy and asthma in childhood. They will present...2008 International Conference in Toronto on Tuesda...d cord blood levels of IL-13, a Th2 type cytokine,...
...d: CRDT), a leading healthcare staffing company, h...arch 31, 2008., Revenue in the quarter was $10,57...revenue of $9,806,540 and an increase of 31% over ...urth quarter of 2007 and $1,712,150 in the first q...
... in very young children may cause some of the adve...er children and adults with the condition, accordi...r findings at the American Thoracic Societys 2008 ...st and sleep specialist who led the study at Ben-G...
...turer,of laser and light-based skin sculpting and ...he introduction of an additional fractional,device...s two new features,-- significantly higher speed, ...aster than competitive instruments, ProFractional-...
Other Medicine News:Health News:Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech 2Health News:Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech 3Health News:Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech 4Health News:Possible biological explanation for C-Section-linked allergies and asthma found 2Health News:Crdentia Announces 2008 First Quarter Results 2Health News:Crdentia Announces 2008 First Quarter Results 3Health News:Crdentia Announces 2008 First Quarter Results 4Health News:Crdentia Announces 2008 First Quarter Results 5Health News:Crdentia Announces 2008 First Quarter Results 6Health News:Crdentia Announces 2008 First Quarter Results 7Health News:Sciton Introduces ProFractional-XC(TM), High-Speed, Dual-Mode Fractional Laser 2
(Date:11/20/2009)..., MINNEAPOLIS, Nov. 20 B...sults for its first quarter ended September 30, 20...uted share, on revenues of $3,263,000. This compa...ted share, on revenues of $3,168,000 for the first...st quarter results, Biotel President and CEO Steve...
(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-U...mes article that questions why currently availabl...ancers are being ignored, ECRI Institute, an indep...ap to the evidence on Finasteride for Prevention ... November 13, 2009, New York Times article, " Dr...
(Date:11/20/2009)..., MEMPHIS, Tenn., Nov. 20 /PRNewswire-FirstCall/...s Division is pleased to announce the signing of a...tates Department of Defense that may lead to the c...revolutionize the treatment of the limbs of soldie...ar, the Defense Advanced Research Projects Agency ...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 1Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 2National new biology initiative offers potential for remarkable and far reaching benefits 9968 1National new biology initiative offers potential for remarkable and far reaching benefits 9968 2National new biology initiative offers potential for remarkable and far reaching benefits 9968 3The Vitality Group Joins Efforts to Improve Health of U S Workforce 57525 1The Vitality Group Joins Efforts to Improve Health of U S Workforce 57525 2
...NTEREY, Calif., Nov. 26 PARI Pharma,s eFlow,elect... GILD ) recent New,Drug Application (NDA) submitta...or marketing approval of aztreonam lysine for inha... for inhalation, delivered by eFlow, is,an investi...stic fibrosis,(CF) who have pulmonary Pseudomonas ...
...Three large, randomized Phase III trials of VELCAD... as oral presentations at the American ...AMBRIDGE, Mass., Nov. 26 Millennium,Pharmaceutica... data from,more than 130 abstracts of VELCADE clin...9th ASH Annual Meeting in Atlanta, Georgia, Decemb...
Other Medicine Technology:PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 2PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 2New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 4New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 5New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 6
Prechopper curved
Medina Irrigating Nucleus Chopper
Rosen Irrigating Nucleus Chopper
Agarwal Irrigating Nucleus Chopper
Medicine Products: